Treatment of systemic autoimmune and inflammatory diseases with rituximab;Rituximab et traitement des maladies auto-immunes et inflammatoires systémiques

Presse Medicale

Volumn 38, Issue 5, 2009, Pages 808-823

  Bussone, Guillaume ^a   Hachulla, Eric ^b   Sibilia, Jean ^c   Michel, Marc ^d   Godeau, Bertrand ^d   Guillevin, Loïc ^a   Mouthon, Luc ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b LILLE UNIVERSITY HOSPITAL   (France)

^c HÔPITAL DE HAUTEPIERRE   (France)

^d UNIVERSITÉ PARIS EST CRÉTEIL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8 INHIBITOR; CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN; METHOTREXATE; NEUTROPHIL CYTOPLASMIC ANTIBODY; PLACEBO; RITUXIMAB;

AUTOIMMUNE CYTOPENIA; AUTOIMMUNE DISEASE; AUTOIMMUNE HEMOLYTIC ANEMIA; AUTOINFLAMMATORY DISEASE; BLOOD CLOTTING FACTOR DEFICIENCY; CRYOGLOBULINEMIA; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; MULTIPLE SCLEROSIS; MYOSITIS; PEMPHIGUS VULGARIS; RHEUMATOID ARTHRITIS; SHORT SURVEY; SYSTEMIC LUPUS ERYTHEMATOSUS; VASCULITIS; VON WILLEBRAND DISEASE;

EID: 65449140296     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lpm.2009.02.002     Document Type: Short Survey

References (94)

1. Edwards J.C., Szczepanski L., Szechinski J., Filipowicz-Sosnowska A., Emery P., Close D.R., et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. The New England journal of medicine 350 (2004) 2572-2581
2. Emery P., Fleischmann R., Filipowicz-Sosnowska A., Schechtman J., Szczepanski L., Kavanaugh A., et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis and rheumatism 54 (2006) 1390-1400
3. Cohen S.B., Emery P., Greenwald M.W., Dougados M., Furie R.A., Genovese M.C., et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy. Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis and rheumatism 54 (2006) 2793-2806
4. Cooper N., Stasi R., Cunningham-Rundles S., Feuerstein M.A., Leonard J.P., Amadori S., et al. The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura. British journal of haematology 125 (2004) 232-239
5. Leandro M.J., Edwards J.C., Cambridge G., Ehrenstein M.R., and Isenberg D.A. An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis and rheumatism 46 (2002) 2673-2677
6. Hatjiharissi E., Xu L., Santos D.D., Hunter Z.R., Ciccarelli B.T., Verselis S., et al. Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the Fc{gamma}RIIIa-158 V/V and V/F polymorphism. Blood 110 (2007) 2561-2564
7. Eisenberg R., and Looney R.J. The therapeutic potential of anti-CD20 "what do B-cells do?". Clinical immunology 117 (2005) 207-213
8. Sfikakis P.P., Boletis J.N., Lionaki S., Vigklis V., Fragiadaki K.G., Iniotaki A., et al. Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial. Arthritis and rheumatism 52 (2005) 501-513
9. Anolik J.H., Barnard J., Owen T., Zheng B., Kemshetti S., Looney R.J., et al. Delayed memory B cell recovery in peripheral blood and lymphoid tissue in systemic lupus erythematosus after B cell depletion therapy. Arthritis and rheumatism 56 (2007) 3044-3056
10. Ahmed A.R., Spigelman Z., Cavacini L.A., and Posner M.R. Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin. The New England journal of medicine 355 (2006) 1772-1779
11. Vo A.A., Lukovsky M., Toyoda M., Wang J., Reinsmoen N.L., Lai C.H., et al. Rituximab and intravenous immune globulin for desensitization during renal transplantation. The New England journal of medicine 359 (2008) 242-251
12. Jasti S., Coyle T., Gentile T., Rosales L., and Poiesz B. Rituximab as an adjunct to plasma exchange in TTP: a report of 12 cases and review of literature. Journal of clinical apheresis 23 (2008) 151-156
13. Ng K.P., Cambridge G., Leandro M.J., Edwards J.C., Ehrenstein M., and Isenberg D.A. B cell depletion therapy in systemic lupus erythematosus: long-term follow-up and predictors of response. Annals of the rheumatic diseases 66 (2007) 1259-1262
14. Dass S., Bowman S.J., Vital E.M., Ikeda K., Pease C.T., Hamburger J., et al. Reduction of fatigue in Sjogren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study. Annals of the rheumatic diseases 67 (2008) 1541-1544
15. Pham T., Fautrel B., Gottenberg J.E., Goupille P., Hachulla E., Masson C., et al. Rituximab (MabThera) therapy and safety management. Clinical tool guide. Joint Bone Spine 75 Suppl 1 (2008) S1-S99
16. Looney R.J., Srinivasan R., and Calabrese L.H. The effects of rituximab on immunocompetency in patients with autoimmune disease. Arthritis and rheumatism 58 (2008) 5-14
17. Burr M.L., Malaviya A.P., Gaston J.H., Carmichael A.J., and Ostor A.J. Rituximab in rheumatoid arthritis following anti-TNF-associated tuberculosis. Rheumatology (Oxford, England) 47 (2008) 738-739
18. Arlet J.B., Dimitri D., Pagnoux C., Boyer O., Maisonobe T., Authier F.J., et al. Marked efficacy of a therapeutic strategy associating prednisone and plasma exchange followed by rituximab in two patients with refractory myopathy associated with antibodies to the signal recognition particle (SRP). Neuromuscul Disord 16 (2006) 334-336
19. Rituxan warning. FDA consumer 2007; 41:3.
20. Calabrese L.H., Molloy E.S., Huang D., and Ransohoff R.M. Progressive multifocal leukoencephalopathy in rheumatic diseases: evolving clinical and pathologic patterns of disease. Arthritis and rheumatism 56 (2007) 2116-2128
21. Bussone G., Ribeiro E., Dechartres A., Viallard J.F., Bonnotte B., Fain O., et al. Efficacy and safety of rituximab in adults' warm antibody autoimmune haemolytic anemia: retrospective analysis of 27 cases. American journal of hematology (2008) 10.1002/ajh.21341
22. Gottenberg JE, Ravaud P, Bardin T, Combe B, Dougados M, Le Löet X et al. Prospective follow-up of rituximab treatment in 965 patients with refractory rheumatoid arthritis (630 patients/year): tolerance and efficacy data from the french registry Air (autoimmunity and rituximab). ACR Meeting 2008: abstract 1190.
23. Mease P.J. B cell-targeted therapy in autoimmune disease: rationale, mechanisms, and clinical application. The Journal of rheumatology 35 (2008) 1245-1255
24. Keystone E., Burmester G.R., Furie R., Loveless J.E., Emery P., Kremer J., et al. Improvement in patient-reported outcomes in a rituximab trial in patients with severe rheumatoid arthritis refractory to anti-tumor necrosis factor therapy. Arthritis and rheumatism 59 (2008) 785-793
25. Rubbert-Roth A, Tak PP, Bombardieri S, Zerbini C, Tremblay JL, Carreño L et al. Efficacy and safety of various dosing regimens of rituximab in patients with active RA: results of a phase III randomized study (MIRROR). ACR Meeting 2008: abstract 363.
26. Emery P, Rigby WF, Combe B, Latinis K, Szczepański LJ, Roschmann RA et al. Efficacy and safety of rituximab (RTX) as first-line biologic therapy in patients (pts) with active rheumatoid arthritis (RA): Results of a Phase III Randomized Controlled Study (SERENE). ACR Meeting. 2008: Abstract 364.
27. Assous N., Gossec L., Dieude P., Meyer O., Dougados M., Kahan A., et al. Rituximab therapy in rheumatoid arthritis in daily practice. The Journal of rheumatology 35 (2008) 31-34
28. Roll P., Dorner T., and Tony H.P. Anti-CD20 therapy in patients with rheumatoid arthritis: predictors of response and B cell subset regeneration after repeated treatment. Arthritis and rheumatism 58 (2008) 1566-1575
29. Owczarczyk K., Hellmann M., Fliedner G., Rohrs T., Maizus K., Passon D., et al. Clinical outcome and B cell depletion in patients with rheumatoid arthritis receiving rituximab monotherapy in comparison with patients receiving concomitant methotrexate. Annals of the rheumatic diseases 67 (2008) 1648-1649
30. Keystone E., Fleischmann R., Emery P., Furst D.E., van Vollenhoven R., Bathon J., et al. Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis. Arthritis and rheumatism 56 (2007) 3896-3908
31. Berentsen S. Rituximab for the treatment of autoimmune cytopenias. Haematologica 92 (2007) 1589-1596
32. Garvey B. Rituximab in the treatment of autoimmune haematological disorders. British journal of haematology 141 (2008) 149-169
33. Stasi R., Pagano A., Stipa E., and Amadori S. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood 98 (2001) 952-957
34. Arnold D.M., Dentali F., Crowther M.A., Meyer R.M., Cook R.J., Sigouin C., et al. Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. Annals of internal medicine 146 (2007) 25-33
35. Godeau B., Porcher R., Fain O., Lefrere F., Fenaux P., Cheze S., et al. Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura: results of a prospective multicenter phase 2 study. Blood 112 (2008) 999-1004
36. Medeot M., Zaja F., Vianelli N., Battista M., Baccarani M., Patriarca F., et al. Rituximab therapy in adult patients with relapsed or refractory immune thrombocytopenic purpura: long-term follow-up results. European journal of haematology 81 (2008) 165-169
37. Zaja F., Battista M.L., Pirrotta M.T., Palmieri S., Montagna M., Vianelli N., et al. Lower dose rituximab is active in adults patients with idiopathic thrombocytopenic purpura. Haematologica 93 (2008) 930-933
38. D'Arena G., Scalzulli P.R., Nobile M., Dell'olio M., Rossi G., and Cascavilla N. Attenuated doses of rituximab for the treatment of adults with autoimmune cytopenias. American journal of hematology 83 (2008) 686-687
39. Provan D., Butler T., Evangelista M.L., Amadori S., Newland A.C., and Stasi R. Activity and safety profile of low-dose rituximab for the treatment of autoimmune cytopenias in adults. Haematologica 92 (2007) 1695-1698
40. Fairweather H., Tuckfield A., and Grigg A. Abbreviated dose rituximab for immune-mediated hematological disorders. American journal of hematology 83 (2008) 554-557
41. Packman C.H. Hemolytic anemia due to warm autoantibodies. Blood reviews 22 (2008) 17-31
42. Quartier P., Brethon B., Philippet P., Landman-Parker J., Le Deist F., and Fischer A. Treatment of childhood autoimmune haemolytic anaemia with rituximab. Lancet 358 (2001) 1511-1513
43. Zecca M., Nobili B., Ramenghi U., Perrotta S., Amendola G., Rosito P., et al. Rituximab for the treatment of refractory autoimmune hemolytic anemia in children. Blood 101 (2003) 3857-3861
44. Petz L.D. Treatment of autoimmune hemolytic anemias. Current opinion in hematology 8 (2001) 411-416
45. King K.E., and Ness P.M. Treatment of autoimmune hemolytic anemia. Seminars in hematology 42 (2005) 131-136
46. Gehrs B.C., and Friedberg R.C. Autoimmune hemolytic anemia. American journal of hematology 69 (2002) 258-271
47. Genty I., Michel M., Hermine O., Schaeffer A., Godeau B., and Rochant H. Caractéristiques des anémies hémolytiques auto-immunes de l'adulte: analyse rétrospective d'une série de 83 patients. Rev Med Interne 23 (2002) 901-909
48. McDonough A.K., Curtis J.R., and Saag K.G. The epidemiology of glucocorticoid-associated adverse events. Current opinion in rheumatology 20 (2008) 131-137
49. Akpek G., McAneny D., and Weintraub L. Comparative response to splenectomy in Coombs-positive autoimmune hemolytic anemia with or without associated disease. American journal of hematology 61 (1999) 98-102
50. Moyo V.M., Smith D., Brodsky I., Crilley P., Jones R.J., and Brodsky R.A. High-dose cyclophosphamide for refractory autoimmune hemolytic anemia. Blood 100 (2002) 704-706
51. Howard J., Hoffbrand A.V., Prentice H.G., and Mehta A. Mycophenolate mofetil for the treatment of refractory auto-immune haemolytic anaemia and auto-immune thrombocytopenia purpura. British journal of haematology 117 (2002) 712-715
52. Hershko C., Sonnenblick M., and Ashkenazi J. Control of steroid-resistant autoimmune haemolytic anaemia by cyclosporine. British journal of haematology 76 (1990) 436-437
53. Shanafelt T.D., Madueme H.L., Wolf R.C., and Tefferi A. Rituximab for immune cytopenia in adults: idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia, and Evans syndrome. Mayo Clin Proc 78 (2003) 1340-1346
54. Trape G., Fianchi L., Lai M., Laurenti L., Piscitelli R., Leone G., et al. Rituximab chimeric anti-CD20 monoclonal antibody treatment for refractory hemolytic anemia in patients with lymphoproliferative disorders. Haematologica 88 (2003) 223-225
55. D'Arena G., Califano C., Annunziata M., Tartarone A., Capalbo S., Villani O., et al. Rituximab for warm-type idiopathic autoimmune hemolytic anemia: a retrospective study of 11 adult patients. European Journal of Haematology 79 (2007) 53-58
56. Ruckert A., Glimm H., Lubbert M., and Grullich C. Successful treatment of life-threatening Evans syndrome due to antiphospholipid antibody syndrome by rituximab-based regimen: a case with long-term follow-up. Lupus 17 (2008) 757-760
57. Berentsen S., Ulvestad E., Gjertsen B.T., Hjorth-Hansen H., Langholm R., Knutsen H., et al. Rituximab for primary chronic cold agglutinin disease: a prospective study of 37 courses of therapy in 27 patients. Blood 103 (2004) 2925-2928
58. Barnett B., Kruse-Jarres R., and Leissinger C.A. Current management of acquired factor VIII inhibitors. Current opinion in hematology 15 (2008) 451-455
59. Wiestner A., Cho H.J., Asch A.S., Michelis M.A., Zeller J.A., Peerschke E.I., et al. Rituximab in the treatment of acquired factor VIII inhibitors. Blood 100 (2002) 3426-3428
60. Stasi R., Brunetti M., Stipa E., and Amadori S. Selective B-cell depletion with rituximab for the treatment of patients with acquired hemophilia. Blood 103 (2004) 4424-4428
61. Berezne A., Stieltjes N., Le-Guern V., Teixeira L., Billy C., Roussel-Robert V., et al. Rituximab alone or in association with corticosteroids in the treatment of acquired factor VIII inhibitors: report of two cases. Transfusion medicine (Oxford, England) 16 (2006) 209-212
62. Mazoyer E., Fain O., Dhote R., and Laurian Y. Is rituximab effective in acquired von Willebrand syndrome?. British journal of haematology (2008) 10.1111/j.1365-2141.2008.07538.x
63. Grimaldi D., Bartolucci P., Gouault-Heilmann M., Martin-Toutain I., Khellaf M., and Godeau B. Rituximab failure in a patient with monoclonal gammopathy of undetermined significance (MGUS)-associated acquired von Willebrand syndrome. Thrombosis and haemostasis 99 (2008) 782-783
64. Agarwal N., Klix M.M., and Burns C.P. Successful management with intravenous immunoglobulins of acquired von Willebrand disease associated with monoclonal gammopathy of undetermined significance. Annals of internal medicine 141 (2004) 83-84
65. Fakhouri F., Vernant J.P., Veyradier A., Wolf M., Kaplanski G., Binaut R., et al. Efficiency of curative and prophylactic treatment with rituximab in ADAMTS13-deficient thrombotic thrombocytopenic purpura: a study of 11 cases. Blood 106 (2005) 1932-1937
66. Merrill JT, Neuwelt CM, Wallace DJ, Shanahan JC, Latinis KM, Oates JC et al. Efficacy and safety of rituximab in patients with moderately to severely active systemic lupus erythematosus (SLE): Results from the randomized, double-blind phase II/III study EXPLORER. ACR Meeting 2008: Abstract L12.
67. Jonsdottir T., Gunnarsson I., Risselada A., Henriksson E.W., Klareskog L., and van Vollenhoven R.F. Treatment of refractory SLE with rituximab plus cyclophosphamide: clinical effects, serological changes, and predictors of response. Annals of the rheumatic diseases 67 (2008) 330-334
68. Albert D., Dunham J., Khan S., Stansberry J., Kolasinski S., Tsai D., et al. Variability in the biological response to anti-CD20 B cell depletion in systemic lupus erythaematosus. Annals of the rheumatic diseases 67 (2008) 1724-1731
69. Lindholm C., Borjesson-Asp K., Zendjanchi K., Sundqvist A.C., Tarkowski A., and Bokarewa M. Longterm clinical and immunological effects of anti-CD20 treatment in patients with refractory systemic lupus erythematosus. The Journal of rheumatology 35 (2008) 826-833
70. Limal N., Cacoub P., Sene D., Guichard I., and Piette J.C. Rituximab for the treatment of thrombotic thrombocytopenic purpura in systemic lupus erythematosus. Lupus 17 (2008) 69-71
71. Cambridge G., Isenberg D.A., Edwards J.C., Leandro M.J., Migone T.S., Teodorescu M., et al. B cell depletion therapy in systemic lupus erythematosus: relationships among serum B lymphocyte stimulator levels, autoantibody profile and clinical response. Annals of the rheumatic diseases 67 (2008) 1011-1016
72. Gunnarsson I., Sundelin B., Jonsdottir T., Jacobson S.H., Henriksson E.W., and van Vollenhoven R.F. Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis. Arthritis and rheumatism 56 (2007) 1263-1272
73. Thanou-Stavraki A., and James J.A. Primary Sjogren's syndrome: current and prospective therapies. Seminars in arthritis and rheumatism 37 (2008) 273-292
74. Pijpe J., van Imhoff G.W., Spijkervet F.K., Roodenburg J.L., Wolbink G.J., Mansour K., et al. Rituximab treatment in patients with primary Sjogren's syndrome: an open-label phase II study. Arthritis and rheumatism 52 (2005) 2740-2750
75. Seror R., Sordet C., Guillevin L., Hachulla E., Masson C., Ittah M., et al. Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjogren's syndrome. Annals of the rheumatic diseases 66 (2007) 351-357
76. Sanchez-Cano D., Callejas-Rubio J.L., Lara-Jimenez M.A., Lopez-Trascasa M., Circadi M., and Ortego-Centeno N. Successful use of rituximab in acquired C1 inhibitor deficiency secondary to Sjogren's syndrome. Lupus 17 (2008) 228-229
77. Meijer JM, Vissink A, Meiners PM, Spijkervet FK, Kallenberg CG, Bootsma H. Rituximab treatment in primary sjögren's syndrome: a double-blind placebo controlled trial. ACR Meeting 2008: abstract 713.
78. Levine T.D. Rituximab in the treatment of dermatomyositis: an open-label pilot study. Arthritis and rheumatism 52 (2005) 601-607
79. Cooper M.A., Willingham D.L., Brown D.E., French A.R., Shih F.F., and White A.J. Rituximab for the treatment of juvenile dermatomyositis: a report of four pediatric patients. Arthritis and rheumatism 56 (2007) 3107-3111
80. Noss E.H., Hausner-Sypek D.L., and Weinblatt M.E. Rituximab as therapy for refractory polymyositis and dermatomyositis. The Journal of rheumatology 33 (2006) 1021-1026
81. Seo P., Specks U., and Keogh K.A. Efficacy of rituximab in limited Wegener's granulomatosis with refractory granulomatous manifestations. The Journal of rheumatology 35 (2008) 2017-2023
82. Sanchez-Cano D., Callejas-Rubio J.L., and Ortego-Centeno N. Effect of rituximab on refractory Wegener granulomatosis with predominant granulomatous disease. J Clin Rheumatol 14 (2008) 92-93
83. Keogh K.A., Wylam M.E., Stone J.H., and Specks U. Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis and rheumatism 52 (2005) 262-268
84. Guillevin L, Cohen P, Pagnoux C, Mahr A, Cottin V, Buchler M et al. Comparison of infliximab and rituximab in Wegener's granulomatosis (WG) refractory to steroids and immunosuppressants: a prospective, randomized study on 21 patients. ACR Meeting. 2008: Abstract 1873.
85. Zaja F., De Vita S., Mazzaro C., Sacco S., Damiani D., De Marchi G., et al. Efficacy and safety of rituximab in type II mixed cryoglobulinemia. Blood 101 (2003) 3827-3834
86. Stubgen J.P. B cell-targeted therapy with rituximab and autoimmune neuromuscular disorders. Journal of neuroimmunology 204 (2008) 1-12
87. Hauser S.L., Waubant E., Arnold D.L., Vollmer T., Antel J., Fox R.J., et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. The New England journal of medicine 358 (2008) 676-688
88. Lebrun C., Bourg V., Tieulie N., and Thomas P. Successful treatment of refractory generalized myasthenia gravis with rituximab. Eur J Neurol 16 (2009) 246-250
89. Renaud S., Gregor M., Fuhr P., Lorenz D., Deuschl G., Gratwohl A., et al. Rituximab in the treatment of polyneuropathy associated with anti-MAG antibodies. Muscle & nerve 27 (2003) 611-615
90. Benedetti L., Briani C., Franciotta D., Carpo M., Padua L., Zara G., et al. Long-term effect of rituximab in anti-mag polyneuropathy. Neurology 71 (2008) 1742-1744
91. Gorson K.C., Natarajan N., Ropper A.H., and Weinstein R. Rituximab treatment in patients with IVIg-dependent immune polyneuropathy: a prospective pilot trial. Muscle & nerve 35 (2007) 66-69
92. Faurschou A., and Gniadecki R. Two courses of rituximab (anti-CD20 monoclonal antibody) for recalcitrant pemphigus vulgaris. International journal of dermatology 47 (2008) 292-294
93. Barrera M.V., Mendiola M.V., Bosch R.J., and Herrera E. Prolonged treatment with rituximab in patients with refractory pemphigus vulgaris. The Journal of dermatological treatment 18 (2007) 312-314
94. Braendstrup P., Bjerrum O.W., Nielsen O.J., Jensen B.A., Clausen N.T., Hansen P.B., et al. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura. American Journal of Hematology 78 (2005) 275-280